Leading British Academic Joins Clerkenwell’s Advisory Board
Clerkenwell is delighted to announce the appointment of esteemed psychedelic expert, Professor Allan Young as clinical advisor.
The UK is a hub for clinical research on psychedelic drugs. Working with the UK’s leading academics will be crucial as Clerkenwell aims to address the need for psychedelic specialist trial services. The advisory board will provide expert guidance in the advancement of Clerkenwell’s strategy in the UK.
Professor Allan Young currently serves as the Chair of Mood Disorders and Director of the Centre for Affective Disorders within the Department of Psychological Medicine at King’s College London. His research focuses on the cause and treatments for severe psychiatric illnesses, particularly mood disorders.
Professor Young previously held academic appointments in a number of universities including the University of Oxford and University of Newcastle upon Tyne where he was the Chair of General Psychiatry. At Imperial College London, he served as the Director of the Centre for Mental Health and Chair of Psychiatry. He also held the position of Leading Edge Endowment Fund Endowed Chair in Research and Director of the Institute of Mental Health within the Department of Psychiatry at the University of British Columbia.
Tom McDonald, Clerkenwell Health CEO, commented “It’s fantastic to have one of the leading minds in the psychiatry and psychedelics sector on board to help us ensure clinical excellence remains central to what we are doing at Clerkenwell Health. We have already worked together on some very interesting new therapeutic elements in an upcoming phase II psilocybin trial and I’m excited to continue pushing the science forward with Professor Young as we support more CRO customers”.